Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Dr. Lal Pathlabs Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹1,581.70
High
₹1,639.90
Price Summary
| Previous Close | ₹1,600.00 |
|---|---|
| Day's Range | ₹1,581.70 - ₹1,639.90 |
| Open | ₹1,615.70 |
| 52 Week Range | ₹1,272.60 - ₹1,770.00 |
| Volume | 4,44,366 |
| Market Cap | ₹0.03 |
| Previous Close | ₹1,601.10 |
|---|---|
| Day's Range | ₹1,582.10 - ₹1,636.20 |
| Open | ₹1,631.75 |
| 52 Week Range | ₹1,272.00 - ₹1,771.30 |
| Volume | 10,587 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 7,109.86 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 1.28 |
| Price/Earning (TTM) | 53.13 |
| TTM EPS (₹) | 30.11 |
| P/E Ratio | 42.52 |
| Book Value(₹) | 10.69 |
| PAT Margin (%) | 20.00 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 31.53 |
| Trade Value ( ₹ in Lacs) | 169.51 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 1.28 |
| Price/Earning (TTM) | 53.13 |
| TTM EPS (₹) | 30.11 |
| P/E Ratio | 42.52 |
| Book Value(₹) | 10.69 |
| PAT Margin (%) | 20.00 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 31.53 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 5772.0 | 23516.0 |
| Expenses | N/A | N/A |
| PBT | 1449.0 | 6213.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1484.0 | 4973.0 |
About Dr. Lal Pathlabs Ltd.
| Founded | 1995 |
|---|---|
| NSE Symbol | LALPATHLAB |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,47,032.09 | 1,879.40 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,83,758.68 | 6,755.25 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,223.98 | 4,399.20 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,692.75 | 8,079.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,214.23 | 1,434.55 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,08,739.11 | 1,333.60 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,230.20 | 2,273.70 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,02,166.27 | 1,049.70 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,01,634.21 | 2,498.60 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 99,747.98 | 1,011.10 | 835.50 - 835.50 |
No Records Found
Latest News
May
2
2026
Posted on May 2nd 2026
Dr. Lal PathLabs informs about update on acquisition
In continuation to its earlier intimation dated April 30, 2026 with respect to acquisition of 100% stake in Shahbazkers Diagnostic Centre (‘SDCPL’) and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Dr. Lal PathLabs has informed that the Company has completed the said acquisition on May 01, 2026 as per the terms and conditions of the Share Purchase Agreement. Pursuant to completion of said acquisition, SDCPL has now become Wholly Owned Subsidiary of the Company. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as amended from time to time, have already been duly intimated in the earlier intimation dated April 30, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Apr
24
2026
Posted on Apr 24th 2026
Dr. Lal PathLabs informs about analysts meet
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs has informed that it attached the invite of the Conference Call for Investors/ Analysts to be held on Thursday, April 30, 2026 at 5:30 pm (IST) to discuss the financial and operating performance for Q4 & FY26.
The above information is a part of company’s filings submitted to BSE.
Read More
May
15
2026
Posted on May 15th 2026
Lupin informs about press release
Lupin has informed that it enclosed a Press Release titled ‘Lupin Inaugurates Atharv Ability, an Advanced Multidisciplinary Neuro-Rehabilitation Center in Delhi’.
The above information is a part of company’s filings submitted to BSE.
Read More
May
15
2026
Posted on May 15th 2026
Dr. Agarwals Health Care informs about updates
Dr. Agarwals Health Care has informed that the Company is in receipt of a Show Cause Notice dated May 14, 2026 (SCN), from the Office of the Assistant Commissioner, GST & Central Excise, Nungambakkam, Chennai 600 034, alleging certain discrepancies in the returns / statements filed by the Company for the financial year 2022-23. The details as required in terms of regulation 30 read with Schedule III of the SEBI Listing regulations and the SEBI Master Circular concerning the aforesaid receipt of show cause notice, are enclosed as Annexure I. This information is also made available on the website of the Company at: https://dragarwals.co.in/dr-agarwals-health-care/#corporate-announcement.
The above information is a part of company’s filings submitted to BSE.
Read More
May
15
2026
Posted on May 15th 2026
Akums Drugs & Pharma - Quaterly Results
The total revenue for the quarter ended March 2026 remained nearly unchanged at Rs. 3383.72 millions.Profit after Tax for the quarter ended March 2026 saw a decline of -44.92% from Rs. 275.89 millions to Rs. 151.97 millions.The company reported a degrowth in operating Profit to 395.16 millions from 497.74 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 3383.72 | 3287.53 | 2.93 | 13487.36 | 13117.84 | 2.82 | 13487.36 | 13117.84 | 2.82 |
| Other Income | 277.29 | 320.50 | -13.48 | 1129.65 | 1241.92 | -9.04 | 1129.65 | 1241.92 | -9.04 |
| PBIDT | 395.16 | 497.74 | -20.61 | 2104.25 | 2626.91 | -19.90 | 2104.25 | 2626.91 | -19.90 |
| Interest | 25.93 | 26.26 | -1.26 | 100.38 | 153.09 | -34.43 | 100.38 | 153.09 | -34.43 |
| PBDT | 342.12 | 471.48 | -27.44 | 1938.68 | 2473.82 | -21.63 | 1938.68 | 2473.82 | -21.63 |
| Depreciation | 124.21 | 100.93 | 23.07 | 455.03 | 395.45 | 15.07 | 455.03 | 395.45 | 15.07 |
| PBT | 217.91 | 370.55 | -41.19 | 1483.65 | 2078.37 | -28.61 | 1483.65 | 2078.37 | -28.61 |
| TAX | 65.94 | 94.66 | -30.34 | 367.25 | 468.39 | -21.59 | 367.25 | 468.39 | -21.59 |
| Deferred Tax | 33.28 | 12.05 | 176.18 | -3.69 | -7.14 | -48.32 | -3.69 | -7.14 | -48.32 |
| PAT | 151.97 | 275.89 | -44.92 | 1116.40 | 1609.98 | -30.66 | 1116.40 | 1609.98 | -30.66 |
| Equity | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 | 306.21 | 306.21 | 0.00 |
| PBIDTM(%) | 11.68 | 15.14 | -22.87 | 15.60 | 20.03 | -22.09 | 15.60 | 20.03 | -22.09 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr. Lal Pathlabs Ltd. is ₹1,600.00 as of 2026-05-15.
The market capitalisation of Dr. Lal Pathlabs Ltd. is ₹26,819.53 as of 2026-05-14.
The 1-year return of Dr. Lal Pathlabs Ltd. is -0.10% as of 2026-05-15.
The P/E ratio of Dr. Lal Pathlabs Ltd. is 42.52 as of 2026-05-15.
The 52-week high and low of Dr. Lal Pathlabs Ltd. are ₹1,770.00 and ₹1,272.60, respectively, as of 2026-05-15.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
